Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit Therapeutics PLC

www.summitplc.com

Latest From Summit Therapeutics PLC

Summit Therapeutics CEO Applauds UK Antibiotics Market Pilot

The world hopes a UK pilot can offer guidance on making novel antibiotics commercially viable, Summit Therapeutics CEO tells Scrip, but adds his lead asset won’t take part this time. 
Companies Research & Development

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

The US election will intensify  the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.

Policy Regulation

Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

Commercial Business Strategies

Scrip Asks…What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

 

Innovation Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • VASTox PLC
  • Summit PLC
  • Summit Corp. PLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Summit Therapeutics PLC
  • Senior Management
  • Glyn Edwards, CEO
    Daniel Elger, Chief Commercial Officer & SVP, R&D
    Richard Vickers, CSO & SVP, R&D
  • Contact Info
  • Summit Therapeutics PLC
    Phone: (44) (0)1235 443 939
    136a Eastern Ave.
    Milton Park
    Abingdon, OX14 4SB
    UK
UsernamePublicRestriction

Register